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Hereditary angioedema is a rare, but potentially life-threatening genetic disorder that results from an autosomal dominant trait.
It is characterized by acute, recurrent attacks of severe local edema, most commonly affecting the skin and mucosa. Swelling in
hereditary angioedema patients does however not always have to be caused by angioedema but can relate to other concomitant
disorders. In this report we are focusing on misdiagnosis in a patient with known hereditary angioedema, whose bleeding episode
caused by idiopathic thrombocytopenic purpura was mistaken for an acute attack of hereditary angioedema. The case illustrates
how clinicians can have difficulties in handling patients with rare diseases, especially in the emergency care setting.
1. Introduction
Hereditary angioedema (HAE), originally described by
Quincke in 1882 [1], is a rare genetic disorder character-
ized by recurrent episodes of subcutaneous and submucosal
swellings in any part of the skin, including the gastrointestinal
tract and upper airway [2, 3]. The disease is caused by
mutations in the gene encoding SERPING1 causing deficiency
of complement C1 inhibitor (C1-INH), a protein involved
in the regulation of the complement, kinin-kallikrein, coag-
ulation, and fibrinolytic systems [4]. The deficiency results
in uncontrolled activation and release of bradykinin, which
causes increased vascular permeability and dilatation with a
resulting edema at the affected site [5, 6]. HAE is inherited in
an autosomal dominant pattern and is estimated to affect 1 in
50,000 individuals, with no clear sex or ethnic variation [7, 8].
There are two classical types of HAE having identical
clinical presentations. HAE type I represents 85% of patients
with C1-INH deficiency and is characterized by a decreased
production of circulating C1-INH. Patients with HAE type
II, approximately 15% of cases, have normal concentrations
of C1-INH but a dysfunctional protein, meaning a low
functional level to be measured [4]. More rarely seen is a
third type of HAE, primarily discovered in women, with
normal fully functional C1-INH levels presenting with the
typical clinical features of C1-INH deficiency. This type has
been associated with mutations in F12, the gene encoding the
plasma protease factor XII (FXII) [9].
For many health care professionals, HAE present an
ongoing challenge due to the rarity and complexity of the clin-
ical presentations, which may involve most organ systems. In
this report we are focusing on misdiagnosis in a patient with
knownHAEwhohad a swelling caused by bleeding attributed
to idiopathic thrombocytopenic purpura (ITP).
2. Case Presentation
A 74-year-old man had recurrent episodic attacks of abdom-
inal pain and swelling involving the upper airways, extrem-
ities, and genitals from the age of three, leading to both
unnecessary appendectomy and later tracheotomy because
of laryngeal edema. However, he was not diagnosed with
hereditary angioedema, before the age of 33 years, when he
was admitted to the emergency unit with a severe swelling
of his face. Biochemical analyses were consistent with HAE
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Figure 1: Ultrasound scan of the face shows a subcutaneous
haematoma around the right masseter muscle measuring 2 cm in
depth. No other pathology was found.
type I and later a family investigation disclosed a splice site
mutation in the SERPING1 gene (c. 1250-1G>A), a mutation
also found in his son and some of his grandchildren. Since
the diagnosis, he has been treated with Danazol and he
is currently followed up at the National HAE Centre once
yearly. After reducing Danazol to the minimum effective
dose (200mg o.d.), he has an average of three relatively mild
attacks per year. The patient is monitored every six months
with liver enzymes, lipid profile, complete blood cell count,
urinalysis, and liver spleen ultrasound. His breakthrough
attacks are treated with injections of C1-INH concentrate
(Berinert).
In 2014 the patient presented at the local emergency room
(ER) with a severe swelling in the lower part of his face
associated with difficulty in swallowing, abdominal pain, and
a few red spots on his extremities. He had no stridor or voice
changes and there were no signs or symptoms of viral infec-
tion before the attack. Apart from the limited purpuric spots,
the clinical presentation imitated HAE swelling, which was
suggested to be the diagnosis. He was treated with C1-INH
concentrate 1000 units intravenously and discharged from the
ER. However petechiae evolved over most of his body and
suddenly a large haematoma presented spontaneously on his
right jaw. He was once again seen at the ER and the clinical
examination revealed edema of the right side of his face and
lips and inside the mouth and throat. Severe swelling over
the right mandibular condyle was found with a palpable, soft,
nonfluctuant discolored mass measuring 3 cm in diameter.
Multiple small petechiae were detected on the extremi-
ties and thorax and in the facial area including mucosal
bleeding inside the mouth. Abdominal examination revealed
no hepatosplenomegaly or abdominal tenderness and nor-
mal bowel sounds were present. Examination of the urine
was remarkable for microscopic haematuria. An ultrasound
scan was performed showing a subcutaneous haematoma
around the right masseter muscle (Figure 1). A computerised
tomography (CT) of the neck, thorax, abdomen, and pelvis
obtained no pathology besides the haematoma identified on
the ultrasound scan. Laboratory tests presented normal white
blood cell count and hemoglobin level. His platelet count was
significantly low at 3× 109/L [normal count: 150–450× 109/L].
Bone marrow aspiration was performed and revealed trilin-
ear marrow hyperplasia with megakaryopoiesis, compatible
with idiopathic thrombocytopenic purpura (ITP). It cameout
that the patient was diagnosed with ITP 10 years earlier, but
he had forgot about this former diagnosis and seemingly it
was not looked up in the ER. He was referred to a medical
department and the tentative diagnosis of HAE was ruled out
and treatment with prednisolone 50mg o.d. was initiated. He
responded well to therapy and was discharged 9 days later
with normal platelet count.The patient tapered prednisolone
over 4 months and today, 1.5 years after the incidence, he has
normal blood counts and is not specifically treated for ITP.
He still receives Danazol 200mg o.d. for HAE, which in fact
may stabilize his ITP as well.
3. Discussion
In most cases, the attacks of HAE follow a predictable
course. Many episodes are preceded by prodromal symptoms
including a tingling or burning sensation in the affected
area. In two-thirds of the patients, a nonpruritic serpiginous
erythematous rash on the trunk, arms, or legs referred to as
erythema marginatum may appear as part of the prodrome
[10, 11]. Our patient did not experience any kind of prodromal
symptoms other than a general discomfort. Swelling attacks
in HAE manifest as recurrent local nonpitting, nonpruritic
subcutaneous or submucosal edema [2, 12, 13]. Classically, the
swelling develops gradually over a period of 12–24 hours and
then slowly subsides within 72 hours. Severe attacks may last
up to 5 days.
Any individual part of the integument can be affected but
is most common in the extremities, abdomen, genitourinary
system, and upper respiratory tract. Approximately 50% of
the attacks involve the abdomen with severe abdominal pain,
nausea, vomiting, and diarrhea as dominant symptoms [2].
Our patient complained about severe abdominal pain, but
there was no pathology in routine laboratory test or at the
abdominal CT. Episodes of swelling may also involve the
upper respiratory tract, including the tongue, pharynx, and
larynx. Our patient’s main complaint was however swelling
in the lower part of his face associated with difficulty in
swallowing and development of a large haematoma of the jaw
associated with multiple small petechiae on the extremities.
Thesemanifestations are not consistent withHAE and should
lead the clinician to consider other differential diagnoses than
angioedema swelling.
There are numerous inciting factors known to the attacks
of HAE. Episodesmay be triggered byminor trauma, surgery,
dental treatment, psychological stress, or the use of certain
medications. In many cases however, the attacks occur with-
out any identifiable trigger [7].Helicobacter pylori infection is
also considered among the causative factors [14].
The role of Helicobacter pylori is strongly proven and
an association between chronic Helicobacter pylori infection
and the occurrence of ITP has been found [15, 16]. Whether
this Gram-negative bacteriumplays a pathophysiological link
with a key role in the pathogenesis could be speculated. We
would recommend our patient to be tested in nearest future.
The classical complement pathway is an important driver
in the pathogenesis of HAE. Increasing evidence suggests a
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contribution of complement activation in ITP [17, 18], the
additional diagnosis for our patient. It could be considered
that the disturbance of the coagulation systemmight increase
the consumption of C1 and C1-INH and hereby act as a
contributing cause in the development of HAE attacks. A
correlation between ITP and angioedemahas however not yet
been described in the literature.
As illustrated in the disease history of our patient, onset
of symptoms in HAE typically occurs in childhood and
accelerates during adolescence. Despite the early onset in life,
some patients are not diagnosed until adulthood, as there
often is a significant diagnostic delay [3, 19].
The diagnosis of HAE should be suspected based on a
history of recurrent attacks of angioedema or abdominal
pain without associated urticaria [20]. Often the patient
reports a family history of the condition but as 25% of
the cases are caused by spontaneous mutations, having no
family history does not rule out the diagnosis [13]. Laboratory
testing is essential and required to confirm the diagnosis
[4, 13]. It is not necessary to make an extensive paraclinical
investigation every time the HAE patient is hospitalized, as
most patients are self-administrating their attacks at home
without any laboratory tests. Nevertheless, it is important to
remain critical when something in the clinical demonstration
does not agree with the overall picture. The diagnosis of ITP
had already been demonstrated in the patient a decade earlier
but it was not before the laboratory test had been performed
that the diagnosis was reconsidered.
The therapeutic treatment of HAE can be divided into
two regimens: the management of acute attacks and long-
term prophylaxis [20, 21]. The treatment of choice in an
acute attack consists of replacement with C1-INH concen-
trate (plasma-derived: Berinert, Cinryze or recombinant:
Ruconest) and bradykinin B2 receptor antagonist (Firazyr)
or, if those are unavailable, fresh-frozen plasma (contains C1-
INH) [20–22]. Future attacks can be prevented by the use of
attenuated androgens and the drug most frequently used is
Danazol [21]. Although long-term prophylaxis with attenu-
ated androgen is effective, it must be regarded critically due
to a severe profile of side effects. Therapy with Danazol can
be hepatotoxic and affect serum lipid levels. Hypertension,
weight gain, acne, virilization, menstrual irregularities, and
depression are also common [20, 21, 23].More rare side effects
as haematuria have been demonstrated [24]. Therefore, the
microscopic haematuria found in this patient could be a
result of the treatment although his low platelet count is more
likely the cause. Due to the adverse event profile, all patients
treated with Danazol must be monitored every six months
with blood tests, urinalysis, and liver spleen ultrasound [23]
as performed in our patient. Danazol is not only effective as
long-term prophylaxis in HAE but also a good alternative
therapeutic approach as treatment in ITP [25, 26]. This may
explain why the patient did not have any symptoms of ITP
for a long period of time as it turns out that he was possibly
treated for both diseases. The side effects of Danazol are
known to be dose dependent and therefore the dose had
cautiously been reduced a few years earlier to achieve the
lowest recommended effective dose at 200mg daily [21].
When we tried a further dose reduction, he experienced the
reported incident and had a relapse of ITP.
The diagnosis of HAE is often overlooked, as many of its
symptoms mimic those of several other common conditions
which is demonstrating diffuse swelling and abdominal
discomfort [27, 28]. However, the clinical challenge is also
seen the other way around. Swellings in HAE patients do not
always have to be caused by angioedema but can relate to
other concomitant disorders as demonstrated in this case. In
fact, it is commonly seen that less experienced clinicians can
have difficulties in looking beyond a rare initial diagnosis as
they are concentrating too much on making the symptoms
fit the original diagnosis. A thoroughly clinical examination
in HAE patients is therefore essential like in other patients,
giving the physicians the opportunity of looking outside the
box and avoiding mental shortcuts [29]. If the clinical picture
does not fit, it is most likely not the right diagnosis.
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